What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Ozanimod shows moderate benefit over placebo in achieving clinical remission for both TNF-alpha inhibitor-naive and TNF-alpha inhibitor-experienced subgroups, as evidenced by the phase 3 TRUENORTH trial. However, there is no direct evidence comparing ozanimod with standard treatments, leading to a moderate rating.
Does the economic case hold at the expected price? — Cost effectiveness
Ozanimod is considered cost-effective compared to most treatments, with ICERs within acceptable ranges, except when compared to infliximab in the TNF-alpha inhibitor-naive subgroup. This suggests a defensible cost-effectiveness profile.
Is there quality-of-life evidence payers weigh? — Quality of life
The committee noted that ulcerative colitis significantly impacts quality of life, and ozanimod’s ability to induce remission is likely to improve HRQoL. However, specific HRQoL data from validated instruments were not detailed in the document, leading to a moderate rating.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Ozanimod has a good safety profile with manageable adverse effects, primarily mild to moderate. The committee acknowledged the importance of safety in treatment decisions, supporting a strong rating.
Was the drug compared against what payers expect? — Comparator Selection
The document indicates that while ozanimod was compared to relevant treatments, the lack of direct head-to-head trials necessitated reliance on indirect comparisons, which introduces some uncertainty.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population in TRUENORTH is representative of the intended patient population in Healthcare practice, with appropriate subgroup analyses based on TNF-alpha inhibitor experience, supporting a strong rating.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Ozanimod can be integrated into existing treatment pathways with minor adjustments, as it provides a new oral option for patients who have not responded to conventional therapies.
Are the wider system costs understood? — Resource Use and Cost Implications
The budget impact of ozanimod is manageable, and the commercial arrangement provides a discount, indicating a favorable resource use profile.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence base is supported by a phase 3 RCT and network meta-analyses, although some limitations in estimating baseline placebo risk were noted. Overall, the evidence is robust.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
While there are uncertainties regarding the efficacy estimates due to the reliance on indirect comparisons, the context of unmet need and the potential benefits of ozanimod mitigate some concerns.
